The effect of enalapril on serum prolactin. 1983

W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese

Twelve healthy male volunteers received single daily oral doses of enalapril (EN) 10 mg for 8 consecutive days. Serum samples for prolactin (PRL) assay were taken on day 0 (baseline) at 12.00 h and 16.00 h, and on days 1 and 8 at 08.00 h (pre-drug), 12.00 h and 16.00 h. The 08.00 h values on day 1 served as the pre-drug baseline. There were no significant changes from baseline in serum PRL levels on days 1 and 8. All mean serum PRL levels on day 8 were significantly (P less than 0.01) lower than the upper limit of the normal range (2-15 ng/ml) found for healthy males in this laboratory. It is concluded that therapeutic doses of EN (10 mg/day, p.o.) for 8 consecutive days do not raise mean serum PRL levels above the normal range in healthy male volunteers.

UI MeSH Term Description Entries
D008297 Male Males
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
November 1978, British medical journal,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
November 1992, The Journal of clinical psychiatry,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
November 1981, Acta endocrinologica,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
January 1987, Medicina,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
January 1986, International journal of fertility,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
February 1989, Journal of anatomy,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
December 1979, The American journal of psychiatry,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
January 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
August 1975, Research communications in chemical pathology and pharmacology,
W R McNabb, and B A Brooks, and F Noormohamed, and A F Lant, and H J Gomez, and V J Cirillo, and M Hichens, and J A Bolognese
March 1976, Archives of general psychiatry,
Copied contents to your clipboard!